ClinicalTrials.gov record
Active, not recruiting Phase 3 Interventional Results available

Study on Olaparib Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer

ClinicalTrials.gov ID: NCT03732820

Public ClinicalTrials.gov record NCT03732820. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced May 6, 2026, 4:24 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

A Randomised, Double-blind, Placebo-controlled, Multicentre Phase III Study of Olaparib Plus Abiraterone Relative to Placebo Plus Abiraterone as First-line Therapy in Men With Metastatic Castration-resistant Prostate Cancer (PROpel Study)

Study identification

NCT ID
NCT03732820
Recruitment status
Active, not recruiting
Study type
Interventional
Phase
Phase 3
Lead sponsor
AstraZeneca
Industry
Enrollment
895 participants

Conditions and interventions

Interventions

  • abiraterone acetate Drug
  • olaparib Drug

Drug

Eligibility (public fields only)

Age range
18 Years to 99 Years
Sex
Male
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Oct 30, 2018
Primary completion
Jul 29, 2021
Completion
Apr 26, 2026
Last update posted
Jan 28, 2026

2018 – 2026

United States locations

U.S. sites
28
U.S. states
18
U.S. cities
26
Facility City State ZIP Site status
Research Site Birmingham Alabama 35209
Research Site Anchorage Alaska 99503
Research Site Tucson Arizona 85704
Research Site Tucson Arizona 85741
Research Site Clovis California 93611
Research Site Los Angeles California 90027
Research Site Los Angeles California 90073
Research Site Sacramento California 95817
Research Site San Diego California 92123
Research Site Denver Colorado 80211
Research Site Lisle Illinois 60532
Research Site Jeffersonville Indiana 47130
Research Site New Orleans Louisiana 70112
Research Site Detroit Michigan 48202
Research Site Grand Rapids Michigan 49503
Research Site St Louis Missouri 63106
Research Site Bozeman Montana 59715
Research Site Omaha Nebraska 68130
Research Site Paramus New Jersey 07652
Research Site Brooklyn New York 11220
Research Site New Hyde Park New York 11042
Research Site Rochester New York 14642
Research Site Syracuse New York 13210
Research Site Durham North Carolina 27710
Research Site Philadelphia Pennsylvania 19111
Research Site Charleston South Carolina 29425
Research Site Myrtle Beach South Carolina 29572
Research Site Milwaukee Wisconsin 53226

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

Non-U.S. locations

This page focuses on the U.S. directory. The official record also lists 104 non-U.S. sites.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT03732820, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 28, 2026 · Synced May 6, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT03732820 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →